ALDH2 deficiency exacerbates acrolein-mediated neuropathology in multiple sclerosis

Area of Science:

• Neuroscience
• Immunology
• Toxicology

Background:

• Acrolein, a pro-inflammatory aldehyde, is implicated in multiple sclerosis (MS) pathology.
• Aldehyde dehydrogenase 2 (ALDH2) scavenges acrolein, suggesting a potential protective role.
• The ALDH2*2 deficiency genotype may influence susceptibility to worsened MS symptoms.

Purpose of the Study:

• To investigate the impact of ALDH2 deficiency (ALDH2*2 genotype) on multiple sclerosis severity using a mouse model.
• To determine if ALDH2 deficiency exacerbates neuroinflammation, neuronal damage, and behavioral deficits in experimental autoimmune encephalomyelitis (EAE).

Main Methods:

• Utilized the experimental autoimmune encephalomyelitis (EAE) mouse model to simulate multiple sclerosis.
• Compared disease progression and pathological markers in ALDH2*2 mice versus wild-type mice.
• Assessed behavioral deficits, neuropathic pain, inflammatory markers, glutamate transporter function, demyelination, and neuronal loss.

Main Results:

• ALDH2*2 mice with EAE exhibited significantly heightened behavioral deficits and neuropathic pain.
• Enhanced expression of acrolein, inflammatory markers, and glutamate transporter dysfunction were observed in ALDH2*2 EAE mice.
• ALDH2*2 EAE mice showed increased demyelination and a trend towards neuronal loss, indicating impaired neuroprotection.
• Control ALDH2*2 and wild-type mice did not display significant behavioral or physiological differences.

Conclusions:

• ALDH2 plays a critical neuroprotective role in the pathogenesis of experimental autoimmune encephalomyelitis.
• Individuals with ALDH2*2 deficiency may experience more severe symptoms in acrolein-mediated diseases like multiple sclerosis.
• Targeting acrolein and enhancing ALDH2 activity could offer novel therapeutic strategies for neuroprotection in multiple sclerosis.